CADTH | Evidence Driven
CADTH | Evidence Driven

Keytruda for Squamous NSCLC – Details

Details

Files
Generic Name:
Pembrolizumab
Project Status:
Complete
Therapeutic Area:
Squamous NSCLC
Manufacturer:
Merck Canada
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0176-000
NOC Status at Filing:
Pre NOC
Strength:
50 mg/vial & 25 mg/mL
Tumour Type:
Lung
Indications:
Squamous NSCLC
Funding Request:
For the treatment of patients with metastatic squamous NSCLC in combination with carboplatin and either paclitaxel or nab-paclitaxel, in adults with no prior systemic chemotherapy treatment for metastatic NSCLC
Pre Noc Submission:
Yes
Sponsor:
Merck Canada
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
The pCODR Expert Review Committee (pERC) Recommendation was deferred on September 19, 2019 pending additional information from the review team.
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Pembrolizumab (Keytruda) squamous NSCLC – pERC Final Recommendation Final Recommendation January 3, 2020 View PDF
Pembrolizumab (Keytruda) squamous NSCLC – Final Economic Guidance Report Guidance Reports January 3, 2020 View PDF
Pembrolizumab (Keytruda) squamous NSCLC – Final Clinical Guidance Report Guidance Reports January 3, 2020 View PDF
Pembrolizumab (Keytruda) for Squamous NSCLC - pERC Initial Recommendation Initial Recommendation October 31, 2019 View PDF
Pembrolizumab (Keytruda) for Squamous NSCLC - Initial Economic Guidance Reports Guidance Reports October 31, 2019 View PDF
Pembrolizumab (Keytruda) for Squamous NSCLC - Initial Clinical Guidance Reports Guidance Reports October 31, 2019 View PDF
Pembrolizumab (Keytruda) squamous NSCLC – PAG Feedback on Initial Recommendation Feedback January 3, 2020 View PDF
Pembrolizumab (Keytruda) squamous NSCLC – Manufacturer Feedback on Initial Recommendation Feedback January 3, 2020 View PDF
Pembrolizumab (Keytruda) squamous NSCLC – Patient Advocacy Group Feedback on Initial Recommendation Feedback January 3, 2020 View PDF
Pembrolizumab (Keytruda) squamous NSCLC – Clinician Feedback on Initial Recommendation Feedback January 3, 2020 View PDF
Pembrolizumab (Keytruda) squamous NSCLC – Patient Advocacy Group COI Declarations January 3, 2020 View PDF
10) Pembrolizumab (Keytruda) squamous NSCLC – Clinician COI Declarations COI Declarations January 3, 2020 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : January 20, 2020